Data analysis using multiple cohorts has suggested that a higher expression score of ESM-1 was associated with the more aggressive subtype TNBC or HER2+ compare to the HR+ or HER2− subtypes of breast cancers (Figure 6D and Table S1A). Here, ERBB2 is linked to breast cancer.